TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32182798

Group type: EXPERIMENTAL
Intervention: Endurance, organization support, and eudaimonia
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Endurance, organization support, and purpose
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Lower endurance
Number of subjects: 116
Study: 34400438

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Variceal band ligation
Number of subjects: 30
Study: 33074739

Group type: EXPERIMENTAL
Intervention: Dislocation group (50 patients)
Number of subjects: 707

Group type: COMPARATOR
Intervention: No dislocation group (94 patients)
Number of subjects: 707
Study: 34927213

Group type: EXPERIMENTAL
Intervention: Continuous orthodontic force of 150 g applied for 8 weeks, reactivated after 28 days.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intermittent orthodontic force (21 days on, 7 days off) of 150 g applied for 8 weeks.
Number of subjects: 8
Study: 35384391

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT) capsules, administered 5 times over 3 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT) capsules
Number of subjects: 10
Study: 33234419

Group type: EXPERIMENTAL
Intervention: Sweet orange inhalation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Damask rose inhalation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 120
Study: 616120115

Group type: EXPERIMENTAL
Intervention: Diabetic patients (Group 1: well controlled DM, HbA1c ≤7%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diabetic patients (Group 2: poorly controlled DM, HbA1c >7%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 50
Study: 35142713

Group type: EXPERIMENTAL
Intervention: Metformin (1561 ± 470 g·d‐1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resistance Training + Placebo (RT + PLAC)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resistance Training + Metformin (RT + MET)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 14
Study: 34516683

Group type: EXPERIMENTAL
Intervention: Marte Meo and Coordination Meetings (MAC)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Service as Usual (SAU)
Number of subjects: 99
Study: 35561644

Group type: EXPERIMENTAL
Intervention: Baseline food insecurity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline utilities insecurity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child or family care responsibilities at baseline
Number of subjects: 0
Study: 34755012

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAP)
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Open surgery (OP)
Number of subjects: 1025
Study: 32083594

Group type: EXPERIMENTAL
Intervention: Immediate skin-to-skin contact (SSC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard of care (radiant warmer with continuous pulse oximeter monitoring)
Number of subjects: 47
Study: 33371122

Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 48
Study: 35992542

Group type: EXPERIMENTAL
Intervention: Rotational lateral femoral vascular inlay broad fascial flap repair
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional skin flap repair
Number of subjects: 32
Study: 34422259

Group type: EXPERIMENTAL
Intervention: Cobalamin (vitamin B12) supplementation
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Socio-economic status and dietary characteristics
Number of subjects: 561
Study: 35388704

Group type: EXPERIMENTAL
Intervention: Low sodium salt group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Common salt group
Number of subjects: 61
Study: 34647960

Group type: EXPERIMENTAL
Intervention: Modified 2.2-mm trapezoid incision phacoemulsification
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional 2.2-mm incision phacoemulsification
Number of subjects: 130
Study: 35650602

Group type: EXPERIMENTAL
Intervention: AZD0530
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: AZD0530 (open-label extension)
Number of subjects: 20
Study: 33248747

Group type: EXPERIMENTAL
Intervention: Dry Needling and Photobiomodulation (DNP)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dry Needling outside of the trigger point (DNout)
Number of subjects: 43
Study: 32249730

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 191005

Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 191005

Group type: EXPERIMENTAL
Intervention: Genetic liability for depression
Number of subjects: 191005
Study: 32500569

Group type: EXPERIMENTAL
Intervention: Intra-operative fibrinogen concentrate 30 mg.kg-1 (maximum 2 g)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 102
Study: 35791055

Group type: EXPERIMENTAL
Intervention: FUE
Number of subjects: 20

Group type: COMPARATOR
Intervention: FUE + PRP
Number of subjects: 20
Study: 33823045

Group type: EXPERIMENTAL
Intervention: Aversive only (AO, N = 71)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Aversive plus reinforcement (AP, N = 53)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Measurement-only control group (N = 129)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Aversive only (AO)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Aversive plus reinforcement (AP)
Number of subjects: 253
Study: 32219329

Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg (up-titration to 50 mg at week 6)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 67
Study: 36428025

Group type: EXPERIMENTAL
Intervention: Nomogram models for predicting low fertilisation rate (LFR)
Number of subjects: 11598

Group type: EXPERIMENTAL
Intervention: Nomogram models for predicting total fertilisation failure (TFF)
Number of subjects: 11598
Study: 34827483

Group type: EXPERIMENTAL
Intervention: VR‐GAIME
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control game
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 30
Study: 35614845

Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Eating (eTRE; 8:00-16:00) plus Caloric Restriction (CR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Delayed Time-Restricted Eating (dTRE; 12:00-20:00) plus Caloric Restriction (CR)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Caloric Restriction (CR; 8:00-20:00) only
Number of subjects: 37
Study: 33985855

Group type: EXPERIMENTAL
Intervention: CCL11, CCL20, IL17C (biomarkers associated with increased gastric cancer risk)
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: CCL23, MMP1 (biomarkers associated with reduced gastric cancer risk)
Number of subjects: 824
Study: 35152579

Group type: EXPERIMENTAL
Intervention: Bloodletting therapy combined with auricular point sticking, given once every two days for 4 weeks.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Oral solution of levocetirizine hydrochloride, 10 mL once daily for 4 weeks.
Number of subjects: 86
Study: 33092957

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided individualized lung ultrasound stepwise PEEP
Number of subjects: 40

Group type: COMPARATOR
Intervention: PEEP 4 cm.H2 O (Control)
Number of subjects: 40
Study: 36189410

Group type: EXPERIMENTAL
Intervention: Health intervention messages via Internet-based SMS for almost a year
Number of subjects: 6400

Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 6400
Study: 33084149

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg and 25 mg
Number of subjects: 637
Study: 35034364

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 33022987

Group type: EXPERIMENTAL
Intervention: Helianthus tuberosus intake in the morning (5 g/day before breakfast)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Helianthus tuberosus intake in the evening (5 g/day before dinner)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Helianthus tuberosus intake in the morning
Number of subjects: 37
Study: 32149822

Group type: EXPERIMENTAL
Intervention: Preoperative prognostic factors including carbohydrate antigen 19-9, neoadjuvant treatment, tumor size, age, facility type, Charlson/Deyo score, primary site, and sex.
Number of subjects: 7849

Group type: EXPERIMENTAL
Intervention: Cumulative score classification into 3 groups: good, intermediate, and poor prognosis.
Number of subjects: 7849
Study: 32612213

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Cannabinoids
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination of anti-inflammatory diet and cannabinoids
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 35222266

Group type: EXPERIMENTAL
Intervention: Higher serum folate concentrations (Q4≥33.0 ng/ml)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Highest Ca/Mg ratio quartile (≥5.02)
Number of subjects: 110
Study: 32268799

Group type: EXPERIMENTAL
Intervention: FDA e‐cigarette prevention ads
Number of subjects: 557
Study: 32745108

Group type: EXPERIMENTAL
Intervention: Index families (families with multiple first-degree relatives with intracranial aneurysms)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Meta-analysis of families with intracranial aneurysms
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Analysis of ruptured intracranial aneurysms
Number of subjects: 246
Study: 35902851

Group type: EXPERIMENTAL
Intervention: Individualized e-mail support
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Automated e-mail support
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) in form of written information material
Number of subjects: 1250
Study: 34806975

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics (ceftazidime and tobramycin for 14 days, inhaled colistimethate sodium for 3 months)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin for 3 months, inhaled colistimethate sodium for 3 months)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 286

Group type: COMPARATOR
Intervention: Oral antibiotics
Number of subjects: 286
Study: 32317585

Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg, oral, two times daily)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 108
Study: 33181154

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 6668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6668

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 6668
Study: 34062901

Group type: EXPERIMENTAL
Intervention: Mobile-based nutrition and exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile-based exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 33760092

Group type: EXPERIMENTAL
Intervention: SAAF-T intervention group
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: AIM intervention group
Number of subjects: 869

Group type: COMPARATOR
Intervention: SAAF-T control group
Number of subjects: 869

Group type: COMPARATOR
Intervention: AIM control group
Number of subjects: 869
Study: 35523096

Group type: EXPERIMENTAL
Intervention: Traffic-related air pollution exposure (TRAP) during 4-hour sessions on a main road
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control exposure in a park during 4-hour sessions
Number of subjects: 56
Study: 33737340

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 823

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 823
Study: 32041577

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 185
Study: 35784742

Group type: EXPERIMENTAL
Intervention: LY06006 60 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 33511567

Group type: EXPERIMENTAL
Intervention: Pre-alert text message offering opt-out of receiving a mailed fecal immunochemical test (FIT) kit, followed by up to three behaviorally informed text message reminders.
Number of subjects: 440

Group type: COMPARATOR
Intervention: Simple text message reminder as per usual practice (control arm).
Number of subjects: 440
Study: 33493359

Group type: EXPERIMENTAL
Intervention: Alcohol use disorder vignette condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nature MOA beliefs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological MOA beliefs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease MOA beliefs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moral MOA beliefs
Number of subjects: 0
Study: 32628726

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mammography screening in high-risk populations
Number of subjects: 0
Study: 35596030

Group type: EXPERIMENTAL
Intervention: Ertugliflozin (5 and 15 mg pooled)
Number of subjects: 7697

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7697
Study: 34192387

Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W to CZP 200 mg Q2W
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo to CZP 200 mg Q2W
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W (escape arm)
Number of subjects: 261
Study: 32932231

Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (300 mg caffeine, 6 g sugars)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (0 mg caffeine, 0 g sugars)
Number of subjects: 14
Study: 35438367

Group type: EXPERIMENTAL
Intervention: High fresh gas flow (HFGF) at 4 L/min with sevoflurane vaporizer setting of 2.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low fresh gas flow (LFGF) at 1 L/min with sevoflurane vaporizer setting of 8%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High fresh gas flow (HFGF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low fresh gas flow (LFGF)
Number of subjects: 60
Study: 34015228

Group type: EXPERIMENTAL
Intervention: Narrow Band Ultraviolet B (NBUVB) with 311-313 nm, initial dose of 250 mJ/cm2, thrice a week for 8 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Red Light-Emitting Diodes (LED) with wavelengths 633 ± 6 nm, power density of 80 mW/cm2, thrice a week for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Erythromycin (Control)
Number of subjects: 45
Study: 34058431

Group type: EXPERIMENTAL
Intervention: Sub-Tenon injection of 0.15 ml of 0.01% MMC diluted with preservative free lidocaine 2% (n = 27)
Number of subjects: 49

Group type: COMPARATOR
Intervention: MMC-infused sponges soaked in 0.02% MMC (n = 29)
Number of subjects: 49
Study: 32661107

Group type: EXPERIMENTAL
Intervention: Glimepiride + Linagliptin 5 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Glimepiride + Placebo
Number of subjects: 19
Study: 35450990

Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII)
Number of subjects: 79
Study: 35594274

Group type: EXPERIMENTAL
Intervention: Minimal acupuncture treatment (8 sessions over 4 weeks)
Number of subjects: 142
Study: 32993769

Group type: EXPERIMENTAL
Intervention: IOP-lowering medication
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 264
Study: 33113075

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with a preventive oral care program (POCP), n = 25
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group receiving POCP exclusively, n = 23
Number of subjects: 48
Study: 32894857

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day for 5 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 80
Study: 35879360

Group type: EXPERIMENTAL
Intervention: Change-detection task
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 50
Study: 33514274

Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (9.5 mg/24 h)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 94
Study: 32872033

Group type: EXPERIMENTAL
Intervention: ACB + IPACK
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACB alone
Number of subjects: 0
Study: 32713518

Group type: EXPERIMENTAL
Intervention: CCRT plus AC (adjuvant carboplatin/fluorouracil)
Number of subjects: 175

Group type: COMPARATOR
Intervention: CCRT alone
Number of subjects: 175
Study: 36122505

Group type: EXPERIMENTAL
Intervention: Dietary intervention with nutritional reinforcement
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 29
Study: 32839990

Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate (4.26 g in 200 mL of water) plus oxytocin
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (oxytocin only)
Number of subjects: 142
Study: 36217584

Group type: EXPERIMENTAL
Intervention: APC™ Flash‐Free adhesive system
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: APC™ II metallic maxillary precoated premolar brackets
Number of subjects: 186

Group type: COMPARATOR
Intervention: Conventional uncoated metallic bracket
Number of subjects: 186
Study: 33096137

Group type: EXPERIMENTAL
Intervention: Fasted state (5 hours after a glass of water)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fed state (5 hours after a high-calorie, high-fat meal)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fed state
Number of subjects: 8
Study: 35727042

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo-assisted therapy (Placebo-AT)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 127
Study: 32959996

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (weekly multidisciplinary sessions)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: High-intensity intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (low-intensity intervention with comprehensive home-based assessments and advice)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intervention (high-intensity)
Number of subjects: 121
Study: 32536123

Group type: EXPERIMENTAL
Intervention: 60 Gy
Number of subjects: 305

Group type: COMPARATOR
Intervention: 50 Gy
Number of subjects: 305
Study: 34253451

Group type: EXPERIMENTAL
Intervention: Transvaginal hydrolaparoscopy (THL)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 300
Study: 32037569

Group type: EXPERIMENTAL
Intervention: Yoga-based physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33602542

Group type: EXPERIMENTAL
Intervention: Digital scanning technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional impression technique
Number of subjects: 30
Study: 33601679

Group type: EXPERIMENTAL
Intervention: Program to Enhance Adjustment to Residential Living (PEARL)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 219
Study: 32436242

Group type: EXPERIMENTAL
Intervention: Oral ginger for dysmenorrhea
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral and topical ginger for DOMS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Oral and topical ginger for knee AO
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ginger for migraine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Swedish massage with aromatic ginger oil for CLBP
Number of subjects: 21
Study: 36258065

Group type: EXPERIMENTAL
Intervention: lusutrombopag
Number of subjects: 66

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 66
Study: 32215877

Group type: EXPERIMENTAL
Intervention: CRT-D (biventricular defibrillator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CRT-P (biventricular pacemaker)
Number of subjects: 0
Study: 32448159

Group type: EXPERIMENTAL
Intervention: School-based annual mass drug administration (MDA) with praziquantel
Number of subjects: 389
Study: 34705291

Group type: EXPERIMENTAL
Intervention: 81 mg/day aspirin for 4 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 325 mg/day aspirin for 4 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Aspirin exposure
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 74
Study: 34336619

Group type: EXPERIMENTAL
Intervention: Suprascapular plus axillary nerve block (SSAB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Interscalene block (ISB)
Number of subjects: 80
Study: 32912184

Group type: EXPERIMENTAL
Intervention: Pedometer with a goal of 11,000 steps/day (I1)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Pedometer with no goal (I2)
Number of subjects: 265

Group type: COMPARATOR
Intervention: No pedometer (Control)
Number of subjects: 265
Study: 35013093

Group type: EXPERIMENTAL
Intervention: Combination of curcumin, resveratrol, zinc, magnesium, selenium, and vitamin D
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 34088701

Group type: EXPERIMENTAL
Intervention: Recombinant human parathyroid hormone (PTH) (1-84)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 0
Study: 32016520

Group type: EXPERIMENTAL
Intervention: Difficulty grading score (low, medium, high) based on spleen weight, esophagogastric varices, and INR
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Difficulty grading score
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: ROC curve analysis of the scoring system
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: External validation of the scoring system
Number of subjects: 272

Group type: COMPARATOR
Intervention: Comparison of difficulty score with previous grading system
Number of subjects: 272